BDA
The Bermuda Business Development Agency (BDA) will host a virtual panel discussion on Bermuda’s liability market and a Bermuda networking break as part of RIMS, the risk management society® annual conference, a comprehensive risk management event that connects and informs the risk management community. The BDA is proud to be a diamond sponsor of this year’s event, RIMS LIVE, which takes place from April 19–30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406006077/en/
The panel, titled “Changes and Trends in Liability Risk,” will be held on April 22 from 2–3 p.m. ADT. The session will feature Judy Gonsalves, division president at Chubb Bermuda; Saadia Savory, vice president and head of casualty Bermuda at Aspen Insurance; and Kirsten Beasley, interim head, Willis Towers Watson Bermuda. Moderated by Jasmine DeSilva, the BDA’s business development manager for risk and insurance solutions, the panel will explore the current state of the liability market, emerging trends, and the Bermuda market’s response.
“RIMS is the largest risk event of the year — it is a staple in the calendar and the Bermuda market has proudly attended for more than 35 years,” BDA’s CEO Roland Andy Burrows said. “The BDA and Bermuda are extensively committed to supporting and growing the risk management industry here, and participating in the RIMS annual conference is a key part of that. Bermuda continues to work hard to remain at the forefront of commercial trends and drives innovation forward as one of the world’s most important insurance and reinsurance hubs.”
For those who want to connect with Bermuda and the BDA, or find out more, the BDA will host a virtual booth where delegates can learn more about the market, view videos, and engage in live chat. Delegates can also schedule video meetings.
On a lighter note, the BDA will be bringing Bermuda to the attendees during the “Take a Break in Bermuda” networking event on April 20 at 4:30 p.m. ADT, providing an opportunity to hear from the Premier of Bermuda, the Hon. E. David Burt, JP, MP; Bermuda’s Minister of Finance, the Hon. Curtis Dickinson, JP, MP; and BDA CEO Roland Andy Burrows, who will all be speaking from the beautiful Hamilton Princess & Beach Club.
Also from the Hamilton Princess, Jasmine DeSilva and Andrew Holmes, Bermuda brand director for Goslings, will make Bermuda’s famous Rum Swizzle cocktail in Sheila Gosling’s Maytag vintage washing machine from 1964 — the same appliance Bermuda’s late social queen used to prepare drinks in the 1960s. The BDA will also announce the winner of an all-expenses paid trip to Bermuda, including a stay at the Hamilton Princess.
For more information on RIMS and to register for the conference, click here . To schedule a meeting with a BDA team member, please email jasmine@bda.bm or olivia@bda.bm . For more information on the BDA, click here .
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006077/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom